PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|April 22, 2016
Tablet Coating Reduces Production Times
Author(s)Pharmaceutical Technology Editors
The Opadry QX from Colorcon is suitable for tablets containing temperature-sensitive active ingredients.
Advertisement
The Opadry QX is a new, flexible, thin film tablet coating developed by Colorcon. Opadry can be applied over a broad range of process conditions and is suitable for tablets containing temperature-sensitive active ingredients. The high solids, low viscosity ingredients of Opadry QX allow coating across a broad range of process parameters in any type of coating equipment,
“Colorcon carried out extensive studies that clearly demonstrate the process adaptability of Opadry QX,” said Jason Teckoe, senior manager, Product Development at Colorcon in a press announcement. “The results confirm that Opadry QX provides operators with broader latitude to manage critical settings for optimal film coating such as tablet bed temperatures, spray, or air flow rates.”
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement